Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
Niklas Krupka, Daniel C Baumgart Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany Abstract: Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current...
Main Authors: | Krupka N, Baumgart DC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-12-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/designing-biologic-selectivity-for-inflammatory-bowel-disease-ndash-ro-peer-reviewed-article-DDDT |
Similar Items
-
Vedolizumab for inflammatory bowel diseasesI
by: Igor L. Khalif, et al.
Published: (2018-08-01) -
Predicting Response to Vedolizumab in Inflammatory Bowel Disease
by: Joseph Meserve, et al.
Published: (2020-04-01) -
Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01) -
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
by: Benjamin Crooks, et al.
Published: (2020-03-01) -
Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01)